Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2007

Salix Purchases Pepcid and Diuril from Merck & Co. for $55M

  • Salix Pharmaceuticals purchased the U.S. prescription pharmaceutical product rights to Pepcid® Oral Suspension and Diuril® Oral Suspension from Merck & Co. 

    Pepcid Oral Suspension is indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer, and gastroesophageal reflux disease. Diuril Oral Suspension has applications in edema and hypertension.

    Under the terms of the agreement, Salix will make a $55 million up-front payment and up to $6 million in potential sales-based milestone payments to Merck.

    Commenting on this development, Carolyn Logan, president and CEO, Salix, stated, "These marketed products should generate immediate revenue while requiring minimal promotional expense. Pepcid Oral Suspension achieved net sales in the U.S. of approximately $20 million in 2006.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »